Atlanta, Georgia, and Pittsburg, Pennsylvania, March 15, 2021 – Fueling its efforts to accelerate the drug development process, Radyus Research is pleased to announce the addition of Dr. Mark Shlomchik to its scientific advisory board.
Dr. Shlomchik is currently the UPMC Endowed Professor and Chair of the Department of Immunology at the University of Pittsburgh. He is also the co-founder and chief scientific officer at BlueSphere Bio, which is developing personalized T-cell therapy to treat cancer and other diseases. In January, 2021 Bluesphere raised a substantial series B round to push its lead asset towards the clinic.
“I am delighted to join the scientific advisory board at Radyus and look forward to providing guidance,” Dr. Shlomchik said. “Radyus’ mission is to empower academic entrepreneurs and early-stage innovation. As the world battles many persisting diseases, including current and future pandemics, our work will help advance academic insights towards novel therapeutics.”
Dr. Shlomchik has conducted extensive research on B cell immune responses and autoimmune disease. He has published 174 original research and 34 review articles. He earned an M.D./Ph.D. dual degree from the University of Pennsylvania and a B.A. from Harvard.
“We sincerely appreciate Mark’s decision to join our SAB as he and his colleagues have made outstanding contributions to immunology over many years,” Radyus Co-founder and Head of Research Andrew Bush said. “His expertise as both a physician and scientist will be an asset to the Radyus team, and we are thankful to have a world-class immunologist providing advice.”
Also on Radyus’ scientific advisory board is Dr. Richard B. Silverman, the Patrick G. Ryan/ Aon Professor in the departments of chemistry, molecular biosciences, and pharmacology at Northwestern University, and the inventor of Pfizer’s blockbuster Lyrica drug, as well as Dr. Dennis Liotta, another pioneer in the biotech space who serves as the Executive Director of the Emory Institute for Drug Development and Samuel Candler Dobbs Professor in the Department of Chemistry at Emory University. Dr. Liotta co-founded Pharmasset, which was acquired by biopharmaceutical giant Gilead in 2012 for $11.2 billion and developed many antiviral drugs for HIV, hepatitis B and hepatitis C that are now successfully marketed.
About Radyus Research
Radyus Research is a collaborative research organization that offers a wide range of preclinical drug development services combined with comprehensive scientific and strategic consulting. Radyus simplifies the CRO experience by closely collaborating with early-stage biotech and pharma companies to help them achieve their drug and business development goals.
Email us at email@example.com to start the conversation.
Author: Anna Akins, tech reporter at S&P Global